Background: Currently recommended treatment for multidrug-resistant (MDR) tuberculosis (TB) includes 4-8 months of an injectable medication, which is poorly tolerated. We evaluated the impact of coadministering lidocaine on pain and pharmacokinetics of intramuscular injections of amikacin in children with MDR-TB. Methods: Children 8-18 years of age, receiving amikacin for MDR-TB treatment in Cape Town, South Africa, were eligible for this randomized crossover trial. Participants received a 15 mg/kg dose of intramuscular amikacin with and without additional lidocaine (0.2-0.4 mg/kg) on different days and were randomized to the order of the treatments (the sequence). Participants and staff completing evaluations were blinded to sequence. Samples were drawn predose, and at 1, 2, 4, 6 and 8 hours postdose for measurement of plasma amikacin concentrations. Pain was assessed by participants using the Wong Baker FACES pain scale (0-5) predose, immediately after the injection and then at 30 and 60 minutes. Pharmacokinetic measures were calculated using noncompartmental analysis. Results: Twelve children were included, median age 11.5 years (interquartile range [IQR], 9.9-13.4 years). Participant-reported pain scores immediately after the amikacin injection were lower when lidocaine was coadministered: 1.0 (IQR, 0.5-2.0) with lidocaine versus 2.5 (1.0-4.0) without lidocaine (P = 0.004). The median area under the concentration time curve 0-8 and median maximum plasma concentration of amikacin were 109.0 μg × h/mL (IQR,3) and 36.7 μg/mL (IQR, 34.1-40.5) with lidocaine compared with 103.3 μg × h/mL (IQR, 81.7-135.0; P = 0.814) and 34.1 μg/mL (IQR, 35.6-46.4; P = 0.638) without lidocaine, respectively. Conclusions: The coadministration of lidocaine resulted in reduced pain immediately after the injection and did not alter amikacin area under the concentration time curve or maximum plasma concentration.
T reatment outcomes for children with multidrug-resistant (MDR) tuberculosis (TB), defined as resistance to at least both isoniazid and rifampicin, are good, with more than 80% of children successfully treated. 1 However, current MDR-TB treatment regimens are long, requiring 9-18 months of treatment, are poorly tolerated and are associated with frequent and important adverse effects. 2 The second-line injectable anti-TB drugs, including amikacin, kanamycin and capreomycin, have been considered a key component of MDR-TB treatment, with guidelines recommending 4-8 months of an injectable agent. [3] [4] [5] However, their use can result in nephrotoxicity, electrolyte abnormalities and is associated with a risk of permanent sensorineural hearing loss, in up to 25% of children. 6 Recent guidance from the World Health Organization opened the possibility of limiting injectable use in children with less severe TB. However, the newly recommended 9-12--month shortened regimen for MDR-TB includes injectables for at least 4 months, indicating that they will likely remain in use for the near future. 5 In addition to the substantial risk of adverse effects with long-term injectable treatment, their use is complicated by the requirement for parenteral administration. Long-term indwelling catheters, such as portacaths or peripherally inserted centralvenous catheters, are not feasible in most settings with a high burden of MDR-TB. With constrained health care resources, the risk of catheter infection is problematic, and access to rapid, effective treatment of such infections limited. Hence, the vast majority of children with MDR-TB receive these agents as daily intramuscular injections. The injections are painful for adults and children and have been cited as one of the worst aspects of MDR-TB treatment. 7 They are a source of substantial distress for children, their parents and caregivers, as well as for health care workers who are tasked with delivering this painful intervention for months. Strategies to reduce this injection pain and improve the tolerability of the injectables are urgently needed.
Lidocaine, also known as lignocaine, is a local anesthetic agent, which blocks nerve conduction, producing rapid local anesthesia lasting 1-3 hours, with a maximum effect within minutes. When coadministered with intramuscular injections of ceftriaxone 9,10 and penicillin, 11 lidocaine reduced injection pain without affecting the antibiotics' pharmacokinetics. However, this strategy has not been evaluated with the second-line injectable anti-TB medications. The injectables are rapidly absorbed after intramuscular injection and are renally eliminated unchanged. 12, 13 Compared with intravenous injection, there may be increased variability in the rate and degree of absorption of intramuscularly injected aminoglycosides. 14 The impact of lidocaine on the pharmacokinetics of the injectables needs to be considered, as these injectable medications have concentration-dependent activity against Mycobacterium tuberculosis, with the maximum plasma concentration most closely associated with efficacy. 15 Ototoxicity is associated with cumulative drug exposure. 16 The objective of this study was to evaluate the impact of coadministering lidocaine on the pain and pharmacokinetics of intramuscular injections of amikacin in children and adolescents routinely treated for MDR-TB.
MATERIALS AND METHODS

Trial Design
This was a randomized double-blinded 2-period crossover trial.
Participants
Children were eligible to the study if they were 8-18 years of age, routinely treated for MDR-TB with a regimen including amikacin and had received amikacin for at least 14 days. Exclusion criteria included acute illness (enrolment could be deferred), neurologic disability that may have prohibited reporting of pain or a hemoglobin <8 g/dL. Consecutively eligible children were recruited from the Brooklyn Chest Hospital, a provincial TB hospital, which provides long-term care of children with drug-resistant and other complicated forms of TB in Cape Town, South Africa. A sample size of 12 participants was primarily based on pragmatic considerations of the expected number of eligible children. The treatment of MDR-TB was consistent with local and international guidance and generally included 6-7 anti-TB medications given for 12-18 months duration. Amikacin, a second-line injectable anti-TB medication, was included in the regimen of most children with MDR-TB and was given as an intramuscular injection 6 days each week for 2-6 months. Amikacin is recommended for MDR-TB treatment in adults and children but is used off-label for this purpose.
Interventions
Each participant received 2 treatments, each on a single occasion. In treatment A, amikacin was administered without lidocaine; in treatment B, amikacin was administered with lidocaine. Participants were assigned 1:1 to receive treatment A or treatment B first (sequence 1 or sequence 2, respectively). Amikacin was available in 2 mL vials as a 500 mg/2 mL solution for injection (Fresenius, Midrand, South Africa) and was administered as an exact 15 mg/kg dose on the day of sampling. A prespecified weight-banded dose of lidocaine (2% lidocaine solution for injection [20 mg/mL], Fresenius, Midrand, South Africa), within the range of 0.2-0.4 mg/kg/ dose, was drawn up into a syringe along with the amikacin, to be coadministered (Table 1) ; this is well below the maximum safe dose of lidocaine for anesthesia of 3-4 mg/kg. Intramuscular injections were administered with a 21 gauge 1.5-inch needle in the dorsogluteal area on the opposite side as the previous day's injection, according to standard local practice.
Randomization and Blinding
The randomization was generated by the study statistician using a computer-generated list of random numbers with a permutated fixed block randomization having a block size of 4 to assign the order of injections. Allocations were placed in consecutively numbered, sealed, opaque envelopes. 17 Upon enrolment of a participant, 2 unblinded study team members reviewed the allocation, and on the days of pharmacokinetic sampling, they prepared the amikacin injections with or without lidocaine according to the allocation.
Only these 2 study team members responsible for preparing the injections and the study statistician were unblinded. None of these unblinded team members participated in administration of the injections or in pain assessments. After preparation of the injections, opaque tape was placed around the syringe to ensure that small differences in volume of the injection would not be visible to further ensure integrity of the blinding. The study participant and caregivers, and the remainder of the study team, were blinded to the allocation.
Pharmacokinetic Sampling
Pharmacokinetic sampling was completed from 2 to 16 weeks after starting treatment. On the day of sampling, the amikacin dose was administered by the study team together with all the other oral TB medications in the child's MDR-TB regimen. One hour after TB medication was dosed, HIV-infected children were given their antiretroviral drugs. Blood samples were collected predose and then at 1, 2, 4, 6 and 8 hours after amikacin dosing into an Ethylenediaminetetraacetic acid (EDTA)-containing tube and placed on ice. Blood samples were centrifuged and plasma separated and frozen at ˗80°C within 30 minutes.
Amikacin plasma concentrations were measured using a commercial Particle Enhanced Turbidimetric-Inhibition Immunoassay (Architect ci4100, Abbott Laboratories, Diagnostics Division, Abbott Park, IL). The assay was valid over the range 2.0-50 µg/ml, and quality controls were run daily to monitor the assay performance.
Data Collection
Pain was assessed using the Wong-Baker FACES pain scale, a 5-point hedonic scale that has been extensively validated for assessing pain in children older than 7 years of age. 18, 19 The pain scale was translated into Afrikaans and Xhosa, the most frequently used local languages. Using this scale, the children were asked by a study team member to rate the pain in the dorsogluteal area on the side of the day's intramuscular injection. This was done before the injection, to account for preexisting pain from previous injections, immediately after the injection, and then at 30 and 60 minutes postinjection. To account for preexisting pain from previous daily injections, adjusted pain scores were calculated by subtracting the pain score taken just before the injection, from the pain score immediately after injection, and from the scores at 30 and 60 minutes after the injection. HIV status was determined by HIV enzyme-linked immunosorbent assay testing in children > 18 months of age, and HIV DNA polymerase chain reaction in those < 18 months. Weight-for-age z-scores were calculated using the 1990 British growth curves. 20 The study team monitored for adverse events related to the injections during the 60 minutes postinjection. Adverse events were graded according to standard grading criteria 21 and attribution assessed by the study investigator.
Statistical Methods
Demographic and clinical characteristics were summarized using descriptive statistics. Pharmacokinetic measures were estimated using noncompartmental analysis. Observed maximum plasma concentration (C max ) and time to C max (T max ) were recorded directly from the concentration-time data. The area under the concentration time curve from 0 to 8 hours (AUC 0-8 ) was calculated using the linear trapezoidal rule. The AUC (0-∞) was calculated using an exponential extension to the AUC (0-8) . Half-life (t 1/2 ) was denoted as ln2/k el , where k el (elimination rate constant) was the negative slope of the log-linear regression of the 3 final data points of the concentration-time curve. Predose drug concentrations below the lower limit of quantification (BLQ) (2.0 µg/mL) were set to zero in the analysis. For postdose concentrations that were BLQ, the first was set to ½ of the lower limit of quantification, and any subsequent were set to zero.
The primary outcome was adjusted pain scores postinjection. Secondary outcomes were C max , AUC (0-8) , AUC (0-∞) and the number of adverse events at least possibly related to the injection.
The median and interquartile range (IQR) for adjusted pain scores immediately, 30 and 60 minutes after injection and pharmacokinetic parameters (C max , AUC (0-8) , AUC (0-∞) , T max and t 1/2 ) were reported by whether lidocaine was given. Comparisons for each variable (adjusted pain scores and pharmacokinetic measures) by lidocaine status were made using the Wilcoxon matched-pairs signed-ranks test. Geometric means, the exponentiated arithmetic means of log-transformed values, are often better estimators for comparing pharmacokinetic parameters, which are frequently positively skewed and log-normally distributed. Geometric mean ratios (GMRs) were reported with 90% confidence intervals (CIs) and P values to determine if treatment status was associated with C max , AUC (0-8) , AUC (0-∞) or T max . A test drug is considered to be bioequivalent to a reference drug if the 90% CI of the GMR of the AUC and C max between the test and reference fall within 80-125%. Carryover effects for pain and pharmacokinetic measures were assessed statistically using accepted methods, by comparing the mean and median values for the pharmacokinetic parameters and the adjusted pain score outcomes between the 2 sequences (AB vs. BA) using t tests and Wilcoxon rank sum tests, respectively. 22 Pharmacokinetic parameters and other data analysis were performed using Stata 14. 
RESULTS
Between July 2013 and August 2015, 18 participants were screened, with 12 enrolled and randomized (Fig., Supplemental Digital Content 1, http://links.lww.com/INF/D49). Overall, the median age was 11.5 years (IQR, 9.9-13.4); other baseline characteristics are shown by sequence in Table 2 . All randomized participants successfully completed the trial.
Adjusted pain scores are shown in Table 3 . The median adjusted pain score immediately after the injection was lower when administered with lidocaine added: 1.0 (IQR, 0.5-2.0) with lidocaine versus 2.5 (1.0-4.0) without lidocaine (P = 0.004); no significant carryover effects were detected. The median adjusted pain scores 30 and 60 minutes after the injection with lidocaine added were zero; however, this was not statistically different compared with injections without lidocaine.
Summary pharmacokinetic measures are shown in Table 4 and Figure 1 . All 24 predose concentrations were BLQ, and 16 8-hour concentrations were BLQ. One participant had both 6-hour and 8-hour concentrations that were BLQ. There were no statistical differences in AUC 0-8 , AUC 0-∞ or C max when administered with or without lidocaine (Table 3) ; no significant carryover effects were detected. GMRs for pharmacokinetic measures of interest are shown in Table 5 WAZ, weight-for-age z-score. for AUC 0-8 ); there was no clinical or laboratory explanation for these extreme values. No adverse events during the 2 pharmacokinetic sampling days were reported.
DISCUSSION
In this trial, we have shown that the addition of lidocaine to amikacin injections in children and adolescents reduced immediate injection pain, was safe and did not have substantial effects on amikacin pharmacokinetics.
Given previous research with lidocaine coadministered with ceftriaxone and penicillin, it is not surprising that pain was reduced with the addition of lidocaine. In those previous studies, however, lidocaine was used as a diluent to powder for injection, so the final volume for injection was not altered. The amikacin formulation routinely available in our study setting comes as a prepared solution for injection, so the volume for injection was larger when lidocaine was added. Although these additional volumes were relatively small, this may have reduced the anesthetic effect, as larger volumes would be expected to be associated with increased pain. When lidocaine is used as a diluent instead, it may be that the pain would be reduced even further. Some of the reported pain is likely related to the needle penetrating the skin. In this study, we did not use a topical anesthetic agent; however, it is possible that this would further reduce pain and would be an additional measure to improve the tolerability of these intramuscular injections. Although we did not include children < 8 years of age in this study, there is no specific reason to believe that the addition of lidocaine to amikacin injections would not also reduce pain in younger children.
Pain at 30 and 60 minutes postinjection was not statistically different with lidocaine. It may be the study was under-powered to detect a difference. However, it is notable that the median adjusted pain score at these time points was zero on the occasion when administered with lidocaine, meaning that pain was no different than before the injection, and that in a proportion of the patients the adjusted pain score was less than zero, meaning that after the injection pain was lower than before. It may be that the local anesthetic reduced the preexisting pain related to past injections.
There were no significant differences between either the C max or AUC with or without lidocaine. Establishing amikacin bioequivalence between the 2 treatments was not a prespecified aim, and the study was not powered to formally assess this. The 90% CIs for the GMRs did not fall between the targets for bioequivalence, which may be because of the disproportionate effect of a few outlier concentrations. Substantial between occasion variability of the rate and extent of absorption of injectable medications has been described 23, 24 and may explain some of the differences we observed between the 2 treatments in our small sample. Additional work, powered to demonstrate bioequivalence, would confirm more definitively that the addition of lidocaine does not significantly affect amikacin pharmacokinetics. However, it is reassuring that there was not a statistical difference in key pharmacokinetic measures in our study.
Carryover effects were expected to be minimal both for pharmacokinetics, as amikacin is rapidly absorbed and eliminated, and for pain, as injections were always given on the alternate side as the previous day's injection and lidocaine has only an intermediate duration of action (hours).
There were no adverse effects noted on the 2 study days related to the injections. As severe systemic adverse effects are associated with intravascular injection, careful adherence to intramuscular injection administration practices is important. This includes choosing an appropriate injection site and ensuring that the needle is not in a vascular structure after penetration of the needle through the skin and before injection. The study was not designed to evaluate the safety of long-term daily intramuscular lidocaine administration. However, to our knowledge, there is no reason to suspect such adverse effects. Based on these results, we would argue that the coadministration of lidocaine should become routine practice with intramuscular injections of the second-line anti-TB drugs in both children and adults with MDR-TB. Lidocaine should be widely available, as it is used routinely for local anesthesia and is included in the World Health Organization Model List of Essential Medicines. This is likely to be a minimal additional expense for TB programs, particularly given the potential of the intervention to reduce patients' pain and improve the tolerability of this treatment. Although elimination of the need for injectable treatment remains a longer term priority, this is a safe, feasible and clinically impactful intervention that could immediately be implemented, which substantially reduces the pain associated with these very large number of injections and could potentially improve the tolerability of MDR-TB treatment. 
